Stay updated with breaking news from Junshi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint --VV116 has a favorable safety profile and fewer adverse events than PAXLOVID SHANGHAI
(Reuters) - More Shanghai residents were given the freedom to go out to shop for groceries for the first time in nearly two months on Thursday as auth...
BEIJING (Reuters) - An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early pro...
--5th approved indication by NMPA significantly expands eligible patient population...
The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.